Vaccines (Nov 2022)

Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1

  • Li Ou,
  • Krishana Gulla,
  • Andrea Biju,
  • Daniel W. Biner,
  • Tatsiana Bylund,
  • Anita Changela,
  • Steven J. Chen,
  • Cheng-Yan Zheng,
  • Nicole Cibelli,
  • Angela R. Corrigan,
  • Hongying Duan,
  • Christopher A. Gonelli,
  • Wing-Pui Kong,
  • Cheng Cheng,
  • Sijy O’Dell,
  • Edward K. Sarfo,
  • Andrew Shaddeau,
  • Shuishu Wang,
  • Alison Vinitsky,
  • Yanhong Yang,
  • Baoshan Zhang,
  • Yaqiu Zhang,
  • Richard A. Koup,
  • Nicole A. Doria-Rose,
  • Jason G. Gall,
  • John R. Mascola,
  • Peter D. Kwong

DOI
https://doi.org/10.3390/vaccines10111916
Journal volume & issue
Vol. 10, no. 11
p. 1916

Abstract

Read online

Conjugate-vaccine immunogens require three components: a carrier protein, an antigen, and a crosslinker, capable of coupling antigen to carrier protein, while preserving both T-cell responses from carrier protein and B-cell responses from antigen. We previously showed that the N-terminal eight residues of the HIV-1 fusion peptide (FP8) as an antigen could prime for broad cross-clade neutralizing responses, that recombinant heavy chain of tetanus toxin (rTTHC) as a carrier protein provided optimal responses, and that choice of crosslinker could impact both antigenicity and immunogenicity. Here, we delve more deeply into the impact of varying the linker between FP8 and rTTHC. In specific, we assessed the physical properties, the antigenicity, and the immunogenicity of conjugates for crosslinkers ranging in spacer-arm length from 1.5 to 95.2 Å, with varying hydrophobicity and crosslinking-functional groups. Conjugates coupled with different degrees of multimerization and peptide-to-rTTHC stoichiometry, but all were well recognized by HIV-fusion-peptide-directed antibodies VRC34.01, VRC34.05, PGT151, and ACS202 except for the conjugate with the longest linker (24-PEGylated SMCC; SM(PEG)24), which had lower affinity for ACS202, as did the conjugate with the shortest linker (succinimidyl iodoacetate; SIA), which also had the lowest peptide-to-rTTHC stoichiometry. Murine immunizations testing seven FP8-rTTHC conjugates elicited fusion-peptide-directed antibody responses, with SIA- and SM(PEG)24-linked conjugates eliciting lower responses than the other five conjugates. After boosting with prefusion-closed envelope trimers from strains BG505 clade A and consensus clade C, trimer-directed antibody-binding responses were lower for the SIA-linked conjugate; elicited neutralizing responses were similar, however, though statistically lower for the SM(PEG)24-linked conjugate, when tested against a strain especially sensitive to fusion-peptide-directed responses. Overall, correlation analyses revealed the immunogenicity of FP8-rTTHC conjugates to be negatively impacted by hydrophilicity and extremes of length or low peptide-carrier stoichiometry, but robust to other linker parameters, with several commonly used crosslinkers yielding statistically indistinguishable serological results.

Keywords